Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), which may not compare with the analyst estimate of ($0.76). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Darden Restaurants (DRI) Tops Q4 EPS by 3c, Misses on Revenue; Offers FY27 Guidance
• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance